What is the best way to taper clonazepam (a benzodiazepine) using pregabalin (Lyrica)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tapering Clonazepam Using Pregabalin

Gradual benzodiazepine taper remains the primary strategy, with pregabalin serving as an adjunctive agent to manage withdrawal symptoms and anxiety rather than as a direct substitution therapy. The evidence does not support pregabalin as a standalone replacement for clonazepam discontinuation.

Core Tapering Strategy

The standard benzodiazepine taper protocol should be followed: reduce clonazepam dose by 25% every 1-2 weeks 1. This slow taper minimizes withdrawal symptoms including rebound anxiety, hallucinations, seizures, delirium tremens, and in rare cases, death 2. For patients on long-term benzodiazepines (≥1 year), even slower tapers of 10% per month may be better tolerated 3.

Role of Pregabalin as Adjunctive Therapy

Pregabalin can be introduced as an adjunct to help manage withdrawal symptoms and anxiety during the clonazepam taper, but the evidence for its efficacy is mixed:

  • Starting dose: Begin pregabalin at 50-75 mg twice daily or 50 mg three times daily (150 mg/day total) 4, 5
  • Titration: Increase to 300 mg/day after 3-7 days if tolerated, then by 150 mg/day every 3-7 days as needed 4
  • Target dose range: 300-600 mg/day in divided doses (typically 150-300 mg twice daily) 6

Evidence Limitations

The research shows conflicting results on pregabalin's effectiveness:

  • One randomized controlled trial found pregabalin did not significantly increase benzodiazepine-free rates (51.4% vs 37.0% placebo), though it did reduce anxiety scores and withdrawal symptoms 7
  • An observational study reported 52% success rate in achieving benzodiazepine-free status at 12 weeks 8
  • A systematic review concluded that pregabalin is NOT recommended for benzodiazepine discontinuation as most studies failed to show significant differences in discontinuation rates despite improvement in withdrawal symptoms 9

The most consistent finding is that pregabalin reduces withdrawal symptom severity and anxiety during tapering, not that it increases successful discontinuation rates 7, 8.

Practical Implementation Algorithm

  1. Stabilization phase (2-4 weeks):

    • Maintain current clonazepam dose
    • Introduce pregabalin starting at 150 mg/day
    • Titrate pregabalin to 300 mg/day over 1 week based on tolerability
  2. Taper phase (12+ weeks):

    • Reduce clonazepam by 25% every 1-2 weeks (slower if needed)
    • Maintain pregabalin at 300-450 mg/day throughout taper
    • Monitor withdrawal symptoms using standardized scales
    • Pause taper if significant withdrawal symptoms emerge
  3. Benzodiazepine-free phase (6+ weeks):

    • Continue pregabalin for 6 weeks after last clonazepam dose
    • Then taper pregabalin gradually over minimum 1 week 6

Critical Safety Considerations

Avoid concurrent opioid use: Both benzodiazepines and pregabalin can cause CNS depression. If opioids are also prescribed, this creates potentially fatal respiratory depression risk 10, 1. When both benzodiazepines and opioids are present, taper opioids first due to greater risks of benzodiazepine withdrawal 1.

Pregabalin abuse potential: Pregabalin itself has abuse liability and is a Schedule V controlled substance 4. Exercise caution in patients with history of multiple substance use 11. There are case reports of pregabalin dependence requiring its own withdrawal management 12.

Renal dosing: Both clonazepam and pregabalin require dose adjustment in renal impairment. Pregabalin is eliminated primarily by renal excretion 6.

Monitoring Requirements

  • Frequency: Follow up at least monthly during taper, more frequently if struggling 3
  • Withdrawal symptoms: Anxiety, insomnia, abdominal pain, vomiting, diarrhea, diaphoresis, tremor, tachycardia 3
  • Mental health: Screen for depression, suicidal ideation, and substance use disorder 3, 6
  • Cognitive effects: Pregabalin can cause somnolence, dizziness, and mental clouding, particularly problematic in older adults 13

Alternative Approaches

Cognitive behavioral therapy (CBT) significantly increases benzodiazepine taper success rates and should be offered alongside pharmacological management 1, 10. If pregabalin is not effective or tolerated, consider evidence-based psychotherapies and/or antidepressants for anxiety management rather than continuing benzodiazepines 1.

Gabapentin represents an alternative gabapentinoid with similar mechanism but different pharmacokinetics, though evidence for benzodiazepine withdrawal is similarly limited 14.

Bottom Line

Use pregabalin as symptom management during a standard slow benzodiazepine taper, not as a substitution strategy. The 25% dose reduction every 1-2 weeks remains the cornerstone of safe clonazepam discontinuation. Pregabalin at 300-450 mg/day may reduce withdrawal discomfort and anxiety but does not reliably increase discontinuation success rates. Combine with CBT for optimal outcomes and monitor closely for pregabalin's own abuse potential.

References

Guideline

adult cancer pain.

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

Research

Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice.

European psychiatry : the journal of the Association of European Psychiatrists, 2012

Research

Pregabalin as adjunctive therapy in benzodiazepine discontinuation.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2018

Guideline

prevention and control of seasonal influenza with vaccines.

MMWR Recommendations and Reports, 2016

Guideline

a practical approach to using adjuvant analgesics in older adults.

Journal of the American Geriatrics Society (JAGS), 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.